PPAR Research / 2009 / Article / Tab 2

Review Article

Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?

Table 2

The effect of TZDs on CV risk. The table shows a comparison between rosiglitazone and pioglitazone on lipid profile and HbA1c levels in various studies [1923].

TZDs versus placeboPioglitazoneRosiglitazone

Total cholesterolNeutralRaised
HbA1c 1–1.5% 1–1.5%

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.